Ibrutinib

• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants… Not authorised
  2022-501697-19-00 Phase III 1 country Merck Sharp & Dohme LLC
• CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting
  2022-502405-15-01 Phase II 5 countries Klinikum Der Universitat Munchen AöR
• A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractor… Recruiting
  2024-515654-25-00 Phase I/II 2 countries Ascentage Pharma Group Inc.
• A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsacl… Recruiting
  2022-501687-18-00 Phase II 8 countries Incyte Corp.
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting
  2023-508005-24-00 Phase III 11 countries Ascentage Pharma Group Inc.
• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants… Recruiting
  2022-501697-19-01 Phase III 10 countries Merck Sharp & Dohme LLC
• Multi-cohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR Recruiting
  2023-504044-34-00 Phase II 6 countries Janssen - Cilag International
• Evaluaton of ibrutinib therapy for the treatment of autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia/Small Lymphocy… Recruiting
  2023-509793-38-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in R/R PCNSL Recruiting
  2024-513312-95-00 Phase I (FiH) 5 countries Curis Inc.
• Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting
  2022-501808-96-00 Phase II 2 countries Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR
• A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL Recruiting
  2023-507699-38-00 Phase III 9 countries Loxo Oncology Inc.
• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Recruiting
  2023-505347-38-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
• Ibrutinib and Obinutuzumab as first-line treatment for patients with Chronic Lymphocytic Leukemia Recruiting
  2024-514824-18-00 Phase II 1 country Ospedale San Raffaele S.r.l.
• First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in… Ended
  2022-502808-72-00 Phase II 2 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinica… Ended
  2024-512370-94-00 Phase II 1 country Fundacion Geltamo
• OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma… Ended
  2024-512634-15-00 Phase I/II 2 countries LYSARC
• A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat… Ended
  2023-507695-52-00 Phase III 11 countries Loxo Oncology Inc.
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended
  2022-500439-35-00 Phase III 11 countries University Of Cologne
• Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended
  2024-511929-60-00 Phase II 3 countries Universitaetsklinikum Ulm AöR
• Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Ended
  2023-507062-34-00 Phase I (FiH) 5 countries Novartis Pharma AG
• Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomas Ended
  2023-507886-25-00 Phase II 4 countries Association International Extranodal Lymphoma Study Group (IELSG)
• Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia Ended
  2022-500584-12-00 Phase II 2 countries University Hospital Of Ulm AöR
• Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutini… Ended
  2024-511641-18-00 Phase II 1 country Fondazione Italiana Linfomi Ets
• Therapy with ibrutinib for patients with Chronic lymphocytic leukemia with subclonal TP53 aberrations Ended
  2024-514823-41-00 Phase II 1 country Ospedale San Raffaele S.r.l.

Showing 1–24 of 40 trials